LEUKEMIA AND LYMPHOMA
Europe and the US
Linking Knowledge and Practice

3-5 October 2018
DUBROVNIK
Valamar Lacroma Dubrovnik Hotel
Dubrovnik, Croatia

Co-chairs:
Hagop Kantarjian, MD
Professor and Chair
Department of Leukemia
MD Anderson Cancer Center
Houston, TX, USA

Srdan Verstovsek, MD, PhD
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, TX, USA

Boris Labar, MD, PhD
Associate Professor
Department of Medicine
Clinical Hospital Center Zagreb
Zagreb, Croatia

A collaboration by:
The University of Texas
MD Anderson Cancer Center
The School of Medicine
University of Zagreb
Croatian Leukemia and Lymphoma Society
Dear Colleagues and Friends,

It is our great pleasure to announce the multinational congress Leukemia & Lymphoma 2018 that will take place at the Valamar Lacroma Dubrovnik Hotel, Dubrovnik, Croatia, scheduled for 3-5 October 2018. We would like to invite you to be a part of this premier event!

This meeting is a joint effort of The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; The School of Medicine, University of Zagreb, Zagreb, Croatia, organized by Jonathan Wood & Associates, an MDedge Company. The theme of the meeting, Europe and the US Linking Knowledge and Practice, reflects the collaboration to advance the research and treatment of patients with hematologic malignancies globally.

Leukemia & Lymphoma 2018 will host nearly 500 delegates and approximately 50 renowned faculty from the US and Europe. The meeting will provide participants with a unique opportunity for sharing knowledge, skills, and experiences. In addition, this activity will provide a platform for networking with many of the world’s leading experts, focusing on reviewing and assessing best practices and state of the art treatments across the spectrum of hematologic malignancies, including leukemias, lymphoma, myeloma, MDS, MPNs, and transplant.

The meeting program will include presentations, round-table discussions, debates with audience participation, oral abstracts, poster sessions, and a number of informal social gatherings. As the Chairs of Leukemia & Lymphoma 2018, it is our pleasure to invite you to participate in this one-of-a-kind event.

If you would like additional information or have any questions regarding the conference, please email BD@jwoodassoc.com, or contact Damaris Cruz at +1-201-594-0400 or by email, dcruz@jwoodassoc.com

Hagop Kantarjian, MD
Professor Of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, TX, USA

Srdan Verstovsek, MD, PhD
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, TX, USA

Boris Labar, MD, PhD
Associate Professor
Department of Medicine
Clinical Hospital Center Zagreb
Zagreb, Croatia
CORPORATE SPONSORSHIP OPPORTUNITIES

Leukemia & Lymphoma 2018 offers a forum for industry sponsors to participate in the exchange of information and ideas surrounding cutting edge developments in hematologic malignancies. The planning committee, faculty, and attendees alike appreciate the support of our industry partners. Without your contributions, educational events such as Leukemia & Lymphoma 2018 would not be possible.

There are many opportunities for industry to sponsor the conference’s educational programs, meeting materials, and services. Each opportunity promises to provide a significant presence for companies during the conference. Commensurate with the level of contribution, sponsors are acknowledged in all Leukemia & Lymphoma 2018 meeting materials and on the conference website.
<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday, October 03</th>
<th>Thursday, October 04</th>
<th>Friday, October 05</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15</td>
<td>Morning Symposium</td>
<td>Myeloproliferative Neoplasms</td>
<td>Morning Symposium</td>
</tr>
<tr>
<td>7:30</td>
<td></td>
<td></td>
<td>B-Cell Lymphomas</td>
</tr>
<tr>
<td>8:00</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Keynote Address</td>
<td>Myelodysplastic Syndromes</td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Acute Lymphocytic Leukemias</td>
<td>Lunch Symposium</td>
<td>Lunch Symposium</td>
</tr>
<tr>
<td>11:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Acute Myeloid Leukemias</td>
<td>Chronic Myeloid Leukemias</td>
<td>Multiple Myeloma</td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>Acute Myeloid Leukemias</td>
<td>Chronic Lymphocytic Leukemias</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>Acute Myeloid Leukemias</td>
<td>Oral Poster Presentations</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Acute Myeloid Leukemias</td>
<td>Oral Poster Presentations</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Acute Myeloid Leukemias</td>
<td>Oral Poster Presentations</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Acute Myeloid Leukemias</td>
<td>Oral Poster Presentations</td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Dinner</td>
<td>Oral Poster Presentations</td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Day 1

#### Welcome and Introduction of Keynote Presenter
- **14:00-14:10** Welcome and Introduction of Keynote Presenter
  - Boris Labar (Croatia)

#### Keynote Address: State of the Art Therapy for CML
- **14:10 - 15:00** Keynote Address: State of the Art Therapy for CML
  - Hagop Kantarjian (USA)

### Session 1: Acute Lymphocytic Leukemias

**Moderators:** Boris Labar, Farhad Ravandi

#### Prognostic implications of cytogenetic aberrations and molecular mutations in acute leukemia
- **15:05 - 15:20** Prognostic implications of cytogenetic aberrations and molecular mutations in acute leukemia
  - Claudia Haferlack (Germany)

#### Significance of minimal residual disease in the acute leukemias
- **15:25 - 15:40** Significance of minimal residual disease in the acute leukemias
  - Monika Bruggemann (Germany)

#### Impact of TKIs on Philadelphia chromosome+ ALL
- **15:45 - 16:00** Impact of TKIs on Philadelphia chromosome+ ALL
  - Elias Jabbour (USA)

#### Therapeutic options for Philadelphia chromosome-like ALL
- **16:05 - 16:20** Therapeutic options for Philadelphia chromosome-like ALL
  - Sabina Chiaretti (Italy)

#### Treatment of Adolescents and Young Adults with ALL
- **16:25 - 16:40** Treatment of Adolescents and Young Adults with ALL
  - Jean-Pierre Marie (France)

#### How should we treat older patients with ALL?
- **16:45 - 17:00** How should we treat older patients with ALL?
  - Max Topp (Germany)

### Session 2: Acute Myeloid Leukemias

**Moderators:** Boris Labar, Farhad Ravandi

#### Targeted therapy for AML using FLT3 and IDH1/2 inhibitors
- **17:20 - 17:35** Targeted therapy for AML using FLT3 and IDH1/2 inhibitors
  - Stephane de Botton (France)

#### Monoclonal antibodies and checkpoint inhibitors in AML
- **17:40 - 17:55** Monoclonal antibodies and checkpoint inhibitors in AML
  - Farhad Ravandi (USA)

#### CPX351 and other novel therapies for AML
- **18:00 - 18:15** CPX351 and other novel therapies for AML
  - Jeffrey Lancet (USA)

#### CAR T cell therapy for acute leukemia
- **18:20 - 18:35** CAR T cell therapy for acute leukemia
  - Stephen Grupp (USA)

#### How will solving GVHD impact transplantation for acute leukemias?
- **18:40 - 19:00** How will solving GVHD impact transplantation for acute leukemias?
  - Nikolas von Bubnoff (Germany)

### Day 2

#### Morning Symposium
- **07:30 - 09:00** Morning Symposium

### Session 3: Myeloproliferative Neoplasms

**Moderators:** Pierre Fenaux, Srdan Verstovsek

#### Polycythemia Vera: Diagnosis and management
- **09:05 - 09:20** Polycythemia Vera: Diagnosis and management
  - Alessandro Vannucchi (Italy)

#### Primer on atypical myeloproliferative neoplasms
- **09:25 - 09:40** Primer on atypical myeloproliferative neoplasms
  - Andreas Reiter (Germany)

#### What exactly is myelomonocytic leukemia? Differentiating CMML from everything else
- **09:45 - 10:00** What exactly is myelomonocytic leukemia? Differentiating CMML from everything else
  - Nadira Durakovic (Croatia)

#### JAK inhibitors for all classical Philadelphia negative MPN
- **10:05 - 10:20** JAK inhibitors for all classical Philadelphia negative MPN
  - Srdan Verstovsek (USA)

#### The MPN QOL International Study Group: Is quality of life a legitimate therapeutic target?
- **10:25 - 10:40** The MPN QOL International Study Group: Is quality of life a legitimate therapeutic target?
  - Claire Harrison (UK)

#### Stem cell transplantation for Philadelphia chromosome-negative MPNs in 2018
- **10:45 - 11:00** Stem cell transplantation for Philadelphia chromosome-negative MPNs in 2018
  - Jane Apperley (UK)

### Session 4: Myelodysplastic Syndromes

**Moderators:** Pierre Fenaux, Srdan Verstovsek

#### ICUS/CHIP/CCUS: What determines a correct diagnosis?
- **11:20 - 11:35** ICUS/CHIP/CCUS: What determines a correct diagnosis?
  - Ghulam Mufti (UK)

#### Molecular determinants of MDS
- **11:40 - 11:55** Molecular determinants of MDS
  - Luca Malcovati (Italy)

#### Frontline therapy of low-risk MDS
- **12:00 - 12:15** Frontline therapy of low-risk MDS
  - Valeria Santini (Italy)

#### Frontline therapy of high-risk MDS
- **12:20 - 12:35** Frontline therapy of high-risk MDS
  - Uwe Platzbecker (Germany)

#### What novel new therapies may mean for the future of MDS
- **12:40 - 12:55** What novel new therapies may mean for the future of MDS
  - Pierre Fenaux (France)

#### When should transplant be offered as an option for MDS
- **13:00 - 13:20** When should transplant be offered as an option for MDS
  - Mateo Della Porta (Italy)

### Lunch Symposium
- **13:20 - 15:00** Lunch Symposium
SESSION 5: CHRONIC MYELOID LEUKEMIAS
Moderators: Michael Hallek, Hagop Kantarjian
15:00-15:15 Is minimal residual disease as significant in chronic leukemias as it is in acute leukemias?
William Wierda (USA)
15:20-15:35 Modulating the efficacy of tyrosine kinase inhibitors in CML
Jorge Cortes (USA)
15:40-15:55 What have we learned from the CML European Treatment and Outcomes Study?
Michele Baccarani (Italy)
16:00-16:15 How quality of life issues impact choice of therapy for CML: GIMEMA and EORTC Quality of Life Group
Fabio Efficace (Italy)
16:20-16:35 BREAK

SESSION 6: CHRONIC LYMPHOCYTIC LEUKEMIAS
Moderators: Michael Hallek, Hagop Kantarjian
16:35-16:50 Molecular signature of CLL
Davide Rossi (Italy)
16:55-17:10 Frontline therapy in CLL
Michael Hallek (Germany)
17:15-17:30 Therapy of older patients with CLL
Emili Montserrat (Spain)
17:35-17:50 Novel agents in CLL
Susan O’Brien (USA)
17:55-18:15 Transplantation for CLL
Peter Dreger (Germany)

SESSION 7: ORAL POSTER PRESENTATIONS
18:15-19:00 TBA
19:00-20:00 Poster walk reception

DAY 3  Friday, October 5, 2018
7:30-9:00 Morning Symposium

SESSION 7: B-CELL LYMPHOMAS
Moderators: Tim Illidge, Nathan Fowler
9:05-9:20 Overcoming anti-CD20 refractory disease in BCL with newer antibodies
Guillaume Cartron (France)
9:25-9:40 Managing relapsed/refractory Hodgkin lymphoma
Tim Illidge (UK)
9:45-10:00 Targeting the microenvironment in B-cell lymphoma
Nathan Fowler (USA)
10:05-10:20 Next generation approaches in primary CNS lymphoma
Gerald Illerhaus (Germany)
10:25-10:40 Looking beyond R-CHOP in diffuse large B-cell lymphoma
Marek Trneny (Czech Republic)
10:45-11:00 Moving beyond CHOP in mantle cell lymphoma
Simon Rule (UK)
11:25-11:40 BREAK

SESSION 8: T-CELL LYMPHOMAS
Moderators: Madeleine Duvic, Ali Bazarbachi
11:45-12:00 Integrating immunotherapy into treatment paradigms for CTCL
Madeleine Duvic (USA)
12:05-12:20 Targeting the T-cell receptor pathway in peripheral T-cell lymphoma
Pier Luigi Zinzani (Italy)
12:25-12:40 Enhancing targeted therapies with epigenetic agents in PTCL
Owen O’Connor (USA)
12:45-13:05 Is there a role for ASCT in adult T-cell lymphoma?
Ali Bazarbachi (Lebanon)
13:05-14:35 Lunch Symposium

SESSION 9: MULTIPLE MYELOMA
Moderators: Nikhil Munshi, Pieter Sonneveld
14:35-14:50 Prognostic factors in multiple myeloma
Jesus San Miguel (Spain)
14:55-15:10 Managing asymptomatic multiple myeloma
Dirk Hose (Germany)
15:15-15:30 Immunotherapy for multiple myeloma: update on the IMiDS
Nikhil Munshi (USA)
15:35-15:50 Maintenance therapy in multiple myeloma
Pieter Sonneveld (The Netherlands)
15:55-16:10 Minimal residual disease in multiple myeloma
Herve Avet-Loiseau (France)
16:15-16:35 New antibodies for multiple myeloma
Antonio Palumbo (Italy)
16:35 Closing remarks